Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer.

e15010Background: Recent studies have shown Regorafenib (R) and TAS-102 (TAS) to be superior to placebo (P) in refractory metastatic colorectal cancer (mCRC). However, no studies have directly comp...